<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937999</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10212</org_study_id>
    <nct_id>NCT03937999</nct_id>
  </id_info>
  <brief_title>Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.</brief_title>
  <official_title>A Pragmatic Trial of Secondary Prophylaxis With Bezlotoxumab to Prevent C. Difficile Relapse Among Hospitalized Adults Receiving Antibiotics.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether the human monoclonal antibody, bezlotoxumab administered&#xD;
      AFTER acute Clostridioides difficile (C.diff) has resolved, but during a period of subsequent&#xD;
      antibiotic therapy, will eliminate the high risk of C. diff relapse.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clostridioides difficile (C. diff) is a germ (bacteria) that causes life-threatening&#xD;
      diarrhea. It is usually a side-effect of taking antibiotics that affect the normal balance of&#xD;
      bacteria in the intestines. When the &quot;good bacteria&quot; in the intestine are killed by&#xD;
      antibiotics, the C.diff bacteria begin to grow and produce toxins, causing frequent diarrhea&#xD;
      and other symptoms such as abdominal pain or tenderness, loss of appetite, low-grade fever,&#xD;
      nausea and vomiting. C. diff can be treated by using special antibiotics, but it tends to&#xD;
      come back in about 20% of patients. C-diff is problematic because of frequent relapses after&#xD;
      apparent cure. The greatest risk factor for relapse is receipt of subsequent antibiotics, in&#xD;
      the hospital, shortly after being treated.&#xD;
&#xD;
      Zinplavaâ„¢(bezlotoxumab) is an FDA approved human monoclonal antibody designed to prevent the&#xD;
      recurrence of C.diff.This is not an antibiotic, as it does not kill C. diff, but is an&#xD;
      antibody to C. diff toxins, which stops the damage. When Bezlotoxumab is given during a C.&#xD;
      diff infection together with antibiotics to kill C. diff, it decreases the risk that C. diff&#xD;
      will come back by about one-half. Bezlotoxumab is approved for use when given during a C.&#xD;
      diff infection, but it has not been used to prevent C diff in other situations, such as the&#xD;
      one being studied in this research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention group compared to concurrent and historical control groups</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of C.diff infection</measure>
    <time_frame>within 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of C. diff infection</measure>
    <time_frame>within 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of deaths</measure>
    <time_frame>within 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Clostridium Difficile</condition>
  <arm_group>
    <arm_group_label>Bezlotoxumab Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Bezlotoxumab 10mg/kg iv over 60 minutes on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Bezlotoxumab</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group who are eligible as per the inclusion/exclusion criteria to the Bezlotoxumab arm, but not given Bezlotoxumab (Day 0) .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bezlotoxumab</intervention_name>
    <description>Injection: 1,000 mg/40 mL (25 mg/mL) solution in a single-dose vial.</description>
    <arm_group_label>Bezlotoxumab Arm</arm_group_label>
    <other_name>Zinplava</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  C diff diagnosed within 90 days&#xD;
&#xD;
          -  Receipt of high-risk antibiotics for C diff (e.g. Beta-lactams, carbapenems) in an&#xD;
             inpatient setting&#xD;
&#xD;
          -  Age 60 years and older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of current C.diff active antibiotics (oral vancomycin, fidaxomycin,&#xD;
             metronidazole, tigecycline/ doxycycline, nitazoxanide, rifamycin) within 72hrs.&#xD;
&#xD;
          -  Not Expected to survive 8 weeks&#xD;
&#xD;
          -  Prior or planned fecal microbiota transplant or Bezlotoxumab use&#xD;
&#xD;
          -  Congestive heart failure (a potential risk of Bezlotoxumab)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Riska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Riska, MD</last_name>
    <phone>7189206494</phone>
    <email>priska@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bola Omotosho</last_name>
    <phone>7189206565</phone>
    <email>jomotosh@montefiore.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Riska, MD</last_name>
      <phone>718-920-6565</phone>
      <email>priska@montefiore.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Paul Riska</investigator_full_name>
    <investigator_title>Principal Investigator, Dept of Medicine</investigator_title>
  </responsible_party>
  <keyword>clostridium difficile</keyword>
  <keyword>diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

